Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyphyllin VI is a natural steroidal saponin isolated from the rhizomes of *Paris polyphylla*, a plant long used in traditional Chinese medicine for its anti-tumor properties. It has demonstrated significant anti-cancer activity, particularly in colorectal cancer models such as DLD-1 cells. The mechanism of action for polyphyllin VI involves the induction of autophagy-mediated cell death, characterized by the upregulation of autophagy markers (such as LC3-II). Notably, this process appears to be independent of the p53 and caspase-3 apoptotic pathways. Furthermore, polyphyllin VI has shown potential as a chemosensitizer, enhancing the cytotoxic effects of conventional chemotherapeutic agents like doxorubicin, which suggests its potential utility as a complementary therapy for advanced or recurrent colorectal carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyphyllin VI.